Woodline Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Woodline Partners’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-36,855	Closed	-$164K	–	796
2022 Q1	$164K	Sell	36,855 -739,379	-95%	-$2.95M	﹤0.01%	558
2021 Q4	$3.1M	Sell	776,234 -1,326,733	-63%	-$10.1M	0.04%	352
2021 Q3	$18.5M	Buy	2,102,967 +394,044	+23%	+$3.62M	0.3%	96
2021 Q2	$19.4M	Buy	1,708,923 +978,529	+134%	+$11.8M	0.36%	70
2021 Q1	$8.68M	Buy	+730,394	New	+$8.41M	0.19%	136

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Woodline Partners's ALDX Position: Q2 2022 in Review

Woodline Partners sold out of Aldeyra Therapeutics (ALDX) in Q2 2022, closing a stake of 36,855 shares — an estimated $164K sold.

Woodline Partners first reported a position in ALDX in Q1 2021 and held it in 5 quarters. The position peaked at $19.4M in Q2 2021. 95 funds tracked by Wall St. Rank hold ALDX as of Q2 2022.

Woodline Partners reported no remaining Aldeyra Therapeutics position as of Q2 2022 after selling out during the quarter.
Woodline Partners sold 36,855 Aldeyra Therapeutics shares in Q2 2022, an estimated $164K.
Woodline Partners first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 5 quarters.
Woodline Partners's Aldeyra Therapeutics position peaked at $19.4M in Q2 2021.
95 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2022.

Based on Woodline Partners's 13F filing for Q2 2022, filed 15 Aug 2022.